基于TGF-β1、CTGF在糖尿病大鼠肾脏中的表达研究通心络对肾脏的保护作用

doi:10.13418/j.issn.1001-165x.2018.01.014

摘要/Abstract

摘要：

目的　探讨通心络（tongxinluo, TXL）对转化生长因子-β1（transforming growth factor - beta 1，TGF-β1）与结缔组织生长因子（connective tissue growth factor，CTGF）在糖尿病大鼠肾脏中表达的影响，研究通心络对糖尿病大鼠肾脏的保护作用。方法　40只健康雄性SD大鼠随机分为2组，正常对照组（CON组）12只，造模组28只。造模组采用空腹一次性尾静脉注射链脲佐菌素（Streptozotocin，STZ）55 mg/kg制造糖尿病模型，72 h后血糖≥16.7 mmol/L为造模成功。将造模成功的24只大鼠随机分为糖尿病组（DM组）、通心络组（TXL组），每组12只，给药8周后全自动化生化分析仪检测生化指标，电镜观察肾脏组织超微结构，免疫组化法检测TGF-β1、CTGF蛋白水平的表达，Western blot测定肾脏组织中TGF-β1、CTGF蛋白的水平。结果　通心络组与糖尿病组相比肾脏基底膜增厚、系膜基质积聚、足突融合现象均减轻，肾脏组织中TGF-β1、CTGF表达减少。结论　通心络可降低TGF-β1、CTGF在糖尿病大鼠肾组织中的表达，对糖尿病大鼠肾脏具有保护作用。

关键词: 通心络, 　糖尿病大鼠, 　肾脏, 　TGF-&beta, 1, 　CTGF

Abstract:

Objective　To invatigate the effect of Tongxinluo on transforming growth factor beta 1（TGF-β1）and connective tissue growth factor (CTGF) expression in diabetic rat kidney, and effect of tongxinluo on diabetic rats kidney protection.　Methods　The 40 healthy male SD rats were randomly divided into 2 groups, with 12 rats in the normal control group (CON group), and 28 rats in the model group. The model group was used to manufacture diabetes mellitus with a disposable tail vein injection of Streptozotocin (STZ) 55 mg/kg, and the blood glucose was greater than 16.7 mmol/L after 72 hours. 24 rats with successful modeling were randomly divided into diabetic group (DM group), and group (TXL) tongxinluo group, 12 rats in each group. 8 weeks later full automatic biochemical analyzer test was used for biochemical indexes and kidney tissue ultrastructure was observed using electron microscopice. Immunohistochemical method was to detect the expression of TGF-β1, and CTGF on protein level, Western blot method was used for determination of TGF-β1, and CTGF protein levels in kidney tissue.　Results　Compared with the diabetic group, the thickening of the renal basement membrane, the accumulation of mesangial matrix and the fusion of the foot were all reduced, and the expression of TGF-β1 and CTGF in renal tissues decreased. Conclusion Tongxinluo can reduce the expression of TGF-β1 and CTGF in kidney tissues of diabetic rats, and has protective effect on kidney of diabetic rats.

Key words: Tongxinluo;　Diabetic rats;　Kidney;　TGF-β1； , CTGF

刘颖,　张晓妍. 基于TGF-β1、CTGF在糖尿病大鼠肾脏中的表达研究通心络对肾脏的保护作用[J]. 中国临床解剖学杂志, 2018, 36(1): 61-66.

LIU Ying, ZHANG Xiao-yan. Study on the protective effect of Tongxinluo on kidneys of diabetic rats based on the expression of TGF- β1 and CTGF[J]. Chinese Journal Of Clinical Anatomy, 2018, 36(1): 61-66.

参考文献

[1] Leung WK, Gao L, Siu PM, et al. Diabetic nephropathy and endothelial dysfunction: Current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study[J]. Life Sci, 2016, 166:121-130.
[2] Mou X, Zhou DY, Liu YH, et al. Study on the relationship between chinese medicine constitutive susceptibility and diversity of syndrome in diabetic nephropathy[J]. Chin J Integr Med, 2013,19(9):656-662.
[3] Pei Z, Deng Q, Babcock SA, et al. Inhibition of advanced glycation endproduct (AGE) rescues against streptozotocin-induced diabetic cardiomyopathy: Role of autophagy and ER stress[J]. Toxicol Lett, 2017, 284:10-20.
[4] Li W, Cui M, Wei Y, et al. Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist[J]. Cell Physiol Biochem, 2012, 30(3):749-757.
[5] 张诚. 通心络超微粉联合津力达颗粒对糖尿病大鼠的肾脏防治作用及其对TGF-β1/Smad信号转导通路的影响[D]. 河北医科大学, 2014.
[6] Franconi F, Seghieri G, Canu S, et al. Are the available experimental models of type 2 diabetes appropriate for a gender perspective [J] ? Pharmacol Res, 2008, 57(1):6-18.
[7] Cui F, Zou D, Gao Y, et al. Effect of Tongxinluo on nephrin expression via inhibition of Notch1/Snail pathway in diabetic rats[J]. Evid Based Complement Alternat Med, 2015, 2015:424193.
[8] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50.
[9] Hosseini SM, Boright AP, Sun L, et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy[J]. Hum Genet, 2015, 134(2):247-257.
[10]Faherty N, Curran SP, O'Donovan H, et al. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGF-β type II receptor with implications for nephropathic cell phenotypes[J]. J Cell Sci, 2012, 125(Pt 23):5621-5629.
[11]Mohan T, Velusamy P, Chakrapani LN, et al. Impact of EGCG supplementation on the progression of diabetic nephropathy in rats: An insight into fibrosis and apoptosis [J]. J Agric Food Chem, 2017, 65(36):8028-8036.
[12]Galvan DL, Badal SS, Long J, et al. Real-time in vivo mitochondrial redox assessment confirms enhanced mitochondrial reactive oxygen species in diabetic nephropathy[J]. Kidney Int, 2017, 92(5):1282-1287.
[13]Sakai K, Jawaid S, Sasaki T, et al. Transforming growth factor-β-independent role of connective tissue growth factor in the development of liver fibrosis[J]. Am J Pathol, 2014, 184(10):2611-2617.
[14]Zhang D, Shao S, Shuai H, et al. SDF-1α reduces fibronectin expression in rat mesangial cells induced by TGF-β1 and high glucose through PI3K/Akt pathway[J]. Exp Cell Res, 2013, 319(12):1796-1803.
[15]Wang JY, Gao YB, ZHANG N, et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-mesenchymal transition in diabetic nephropathy[J]. Am J Physiol, Renal physiol, 2014, 35(4):513-522.
[16]Cheng L, Cheng Z, Wang Y, et al. Paeoniflorin exerts a nephroprotective effect on concanavalin A-induced damage through inhibition of macrophage infiltration[J]. Diagn Pathol,2015, 10(1):120.
[17]Mao N, Cheng Y, Shi XL, et al. Ginsenoside Rg1 protects mouse podocytes from aldosteronein-duced injury in vitro[J]. Acta pharmacol Sin, 2014, 35(4):513-522.
[18]Sun Q, Meng QT, Jiang Y, et al. Protective effect of ginsenoside Rb1 against intestinal ischemia-reperfusion induced acute renal injury in mice[J]. PloS One, 2013, 8(12):e80859.